AR065092A1 - TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS - Google Patents

TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS

Info

Publication number
AR065092A1
AR065092A1 ARP080100375A ARP080100375A AR065092A1 AR 065092 A1 AR065092 A1 AR 065092A1 AR P080100375 A ARP080100375 A AR P080100375A AR P080100375 A ARP080100375 A AR P080100375A AR 065092 A1 AR065092 A1 AR 065092A1
Authority
AR
Argentina
Prior art keywords
subject
protein kinase
kinase inhibitor
combination therapy
vegf
Prior art date
Application number
ARP080100375A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR065092A1 publication Critical patent/AR065092A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Metodo para tratar tumores usando una terapia de combinacion con inhibidores de la angiogenesis Reivindicacion 1 un metodo para tratar tumores en un sujeto, que comprende administrar a dicho sujeto un antagonista de VEGF y un inhibidor de proteina quinasa donde dicho antagonista de VEGF interfiere con la union de VEGF a un receptor celular, donde dicho inhibidor de proteina quinasa es capazde inhibir al menos la tirosina quinasa receptora de PDGF, y donde dicha administracion es durante un lapso y en una cantidad suficiente para tratar o prevenir dicho tumor en dicho sujeto Reivindicacion 9: el metodo de la reivindicacion 8, donde dicho anticuerpo anti-VEGF es bevacizumab. Reivindicacion 11: el metodo de la reivindicacion 10, donde dicho inhibidor de proteina quinasa es sunitinib o una forma de sal farmaceuticamente aceptable de este. Reivindicacion 19: el metodo de la reivindicacion 1 o 16,que ademas comprende administrar al sujeto uno o varios agentes quimioterapeuticos. Reivindicacion 21, el metodo de la reivindicacion 19, donde los agentes quimioterapeuticos administrados son carboplatino y paclitaxel.
ARP080100375A 2007-02-01 2008-01-30 TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS AR065092A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88768807P 2007-02-01 2007-02-01

Publications (1)

Publication Number Publication Date
AR065092A1 true AR065092A1 (es) 2009-05-13

Family

ID=39674762

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100375A AR065092A1 (es) 2007-02-01 2008-01-30 TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS

Country Status (16)

Country Link
US (1) US20080199464A1 (es)
EP (1) EP2125016A2 (es)
JP (1) JP2010518013A (es)
KR (1) KR20090104847A (es)
CN (1) CN101646458A (es)
AR (1) AR065092A1 (es)
AU (1) AU2008210521A1 (es)
BR (1) BRPI0806414A2 (es)
CA (1) CA2675451A1 (es)
CL (1) CL2008000290A1 (es)
IL (1) IL199799A0 (es)
MX (1) MX2009008132A (es)
RU (1) RU2009132674A (es)
TW (1) TW200838875A (es)
WO (1) WO2008094969A2 (es)
ZA (1) ZA200904860B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962581B2 (en) * 2008-10-30 2015-02-24 The Translational Genomics Research Institute Methods and kits to identify invasive glioblastoma
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
JP6041489B2 (ja) * 2008-11-22 2016-12-07 ジェネンテック， インコーポレイテッド 乳癌の治療のための化学療法と併用した抗ｖｅｇｆ抗体の使用
US20100266589A1 (en) * 2009-04-20 2010-10-21 Eric Hedrick Adjuvant cancer therapy
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
KR20130091750A (ko) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 유방암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
KR20130091746A (ko) * 2010-07-19 2013-08-19 에프. 호프만-라 로슈 아게 췌장암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커
US20130230511A1 (en) * 2012-02-03 2013-09-05 Board Of Regents, The University Of Texas System Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
EP2825558B1 (en) 2012-03-13 2019-05-15 F.Hoffmann-La Roche Ag Combination therapy for the treatment of ovarian cancer
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
RU2516924C1 (ru) * 2012-11-27 2014-05-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации Способ лечения замедленной элиминации метотрексата после его высокодозной инфузии при опухолях головного мозга у детей
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US11180761B2 (en) * 2014-10-15 2021-11-23 City Of Hope PDGFR RNA aptamers
JP6849590B2 (ja) 2014-10-17 2021-03-24 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
KR20180104635A (ko) 2015-12-30 2018-09-21 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN107684624A (zh) * 2016-08-05 2018-02-13 江苏嵌合体生物技术有限公司 表皮生长因子受体相关癌症的组合治疗
CN112168971B (zh) * 2019-07-03 2023-04-04 义慧科技(深圳)有限公司 抗vegf抗体和pdgf/pdgfr抑制剂在制备治疗表达fgf2肿瘤的药物的应用
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN112798377B (zh) * 2021-01-29 2023-03-17 四川大学华西医院 一种荧光淬灭恢复剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00425B (me) * 2003-05-30 2011-10-10 Genentech Inc Liječenje sa anti-vegf antitijelima
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
EA015533B1 (ru) * 2005-03-15 2011-08-30 4Сц Аг N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
BRPI0609957A2 (pt) * 2005-05-12 2010-05-11 Pfizer uso de malato de sunitinib na preparação de um medicamento para o tratamento de cáncer

Also Published As

Publication number Publication date
US20080199464A1 (en) 2008-08-21
AU2008210521A1 (en) 2008-08-07
MX2009008132A (es) 2009-08-12
WO2008094969A3 (en) 2009-04-30
CN101646458A (zh) 2010-02-10
EP2125016A2 (en) 2009-12-02
BRPI0806414A2 (pt) 2011-09-06
IL199799A0 (en) 2010-04-15
CL2008000290A1 (es) 2008-09-05
WO2008094969A2 (en) 2008-08-07
CA2675451A1 (en) 2008-07-08
JP2010518013A (ja) 2010-05-27
ZA200904860B (en) 2010-09-29
RU2009132674A (ru) 2011-03-10
KR20090104847A (ko) 2009-10-06
TW200838875A (en) 2008-10-01

Similar Documents

Publication Publication Date Title
AR065092A1 (es) TERAPIA DE COMBINACIoN CON INHIBIDORES DE LA ANGIOGÉNESIS
Marth et al. Front-line therapy of advanced epithelial ovarian cancer: standard treatment
Pollom et al. Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy
Hassan et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti‐VEGF treatment or docetaxel in a transgenic mouse model
Bullard Dunn et al. Evolving therapies and FAK inhibitors for the treatment of cancer
EA201200560A1 (ru) Специфическая терапия, использующая интегриновые лиганды для лечения рака
RU2016146993A (ru) Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака
MX2009011226A (es) Inhibidores especificos pdgfrbeta.
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
CO6612253A2 (es) Agentas y antagonistas fijadores de notch y metodos para el uso de los mismos
EA201692167A1 (ru) Модуляторы толл-подобных рецепторов
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
RS54156B1 (en) COMBINED THERAPY INCLUDING ALFA5BETA1 ANTAGONISTS
Harry et al. Novel pathways for targeting tumor angiogenesis in metastatic breast cancer
AR085173A1 (es) Terapia de combinacion para el tratamiento de enfermedades oncologicas y fibroticas
EA201000127A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
EA201692470A1 (ru) Фармацевтические комбинации
Joensuu et al. A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer
Morton et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program
CL2011002416A1 (es) Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit.
Yang et al. Cabozantinib (XL184) and R428 (BGB324) inhibit the growth of esophageal squamous cell carcinoma (ESCC)
AR072759A1 (es) Una combinacion sinergica de un anticuerpo anti-egfr y un inmunosupresor, composicion farmaceutica y procedimiento para obtenerla, metodo de deteccion, uso y kit

Legal Events

Date Code Title Description
FB Suspension of granting procedure